Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins
Executive Summary
When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.
You may also be interested in...
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.